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Background: Children with Down syndrome (DS) have an increased risk for acute lymphoblastic leukemia (ALL).
Although previous studies have shown that DS-ALL differs clinically and genetically from non-DS-ALL, much remains
to be elucidated as regards genetic and prognostic factors in DS-ALL.
Methods: To address clinical and genetic differences between DS-ALL and non-DS-ALL and to identify prognostic
factors in DS-ALL, we ascertained and reviewed all 128 pediatric DS-ALL diagnosed in the Nordic countries between
1981 and 2010. Their clinical and genetic features were compared with those of the 4,647 B-cell precursor (BCP)
ALL cases diagnosed during the same time period.
Results: All 128 DS-ALL were BCP ALL, comprising 2.7% of all such cases. The 5-year event-free survival (EFS) and
overall survival (OS) were significantly (P = 0.026 and P = 0.003, respectively) worse for DS-ALL patients with white
blood cell counts ≥50 × 109/l. The age distributions varied between the DS and non-DS cases, with age peaks at 2
and 3 years, respectively; none of the DS patients had infant ALL (P = 0.029). The platelet counts were lower in the
DS-ALL group (P = 0.005). Abnormal karyotypes were more common in non-DS-ALL (P < 0.0001), and there was a
significant difference in the modal number distribution, with only 2% high hyperdiploid DS-ALL cases (P < 0.0001).
The 5-year EFS and 5-year OS were significantly worse for DS-ALL (0.574 and 0.691, respectively) compared with
non-DS-ALL (0.783 and 0.894, respectively) in the NOPHO ALL-1992/2000 protocols (P < 0.001).
Conclusions: The present study adds further support for genetic and clinical differences between DS-ALL and
non-DS-ALL.
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It is well established that children with Down syndrome
(DS) have an increased risk of developing acute leukemia,
with a relative risk of approximately 20 and a cumulative
risk of 2.1% at the age of 5 years [1,2]. Acute lympho-
blastic leukemia (ALL) in DS (DS-ALL) affects 1 in 300
children with this syndrome [2,3] and several studies
have shown that the outcome of DS-ALL is inferior to
that of non-DS-ALL [4-6]. In fact, leukemia is one of
the most common causes of death in individuals with
DS, together with respiratory diseases, congenital cir-
culatory defects, diseases of the digestive system, and
Alzheimer’s disease [7]. The poor prognosis of DS-ALL
has been attributed to a lower remission rate after induc-
tion therapy as well as to a higher degree of treatment-
related toxicity [4,8-11].
In contrast to myeloid leukemia in DS (ML-DS),
which is associated with a transient myeloproliferative
disorder (TMD), DS-ALL does not display any obvious
preleukemic phase [12,13]. Furthermore, specific gen-
etic changes, such as GATA1 mutations in TMD and
ML-DS that would possibly enable early diagnosis and
treatment, seem to be rare in DS-ALL [14], although
deregulation of the CRLF2 gene at Xp22.33/Yp11.32 is
more prevalent in DS-ALL compared with non-DS-
ALL, as are specific mutations in exon 16 of JAK2 at
9p24.1 [15-18]. DS-ALL and non-DS-ALL have been
reported to display similar median ages, gender distri-
butions, and white blood cell (WBC) counts [13].
Thus, no clinical features, apart from the DS pheno-
type, at the time of diagnosis distinguish these two
patient groups.
However, there are clear immunophenotypic differences
between DS-ALL and non-DS-ALL, with mature B-cell
ALL (Burkitt leukemia) and T-cell ALL being exceedingly
rare in patients with DS; virtually all DS-ALL cases display
a B-cell precursor (BCP) phenotype [11,13,19-21]. As
regards acquired genetic differences, although single
nucleotide polymorphism (SNP) analyses have in gen-
eral identified similar microdeletions in DS-ALL and
non-DS-ALL cases [16,22-25], DS-ALL and non-DS-
ALL are to a large extent cytogenetically distinct – DS-
ALL are rarely high hyperdiploid (51–67 chromosomes)
and seldom display MLL rearrangements or t(9;22)(q34;
q11)/BCR-ABL1 [5,20,26,27]. The lack of specific ALL-
associated gene fusions precludes risk group assignment
and hence treatment stratification based on cytogenetics
in most instances of DS-ALL.
In order to address further clinical and genetic differ-
ences between DS-ALL and non-DS-ALL and to identify
prognostic factors in DS-ALL, we have ascertained and
reviewed all pediatric ALL cases included in the Nordic
Society of Pediatric Hematology, Oncology (NOPHO)
registry 1981–2010.Materials and methods
Patients
Between 1981 and 2010, a total of 128 childhood and
adolescent (<18 years) DS-ALL cases were diagnosed in
the Nordic countries (Denmark, Finland, Iceland, Norway,
and Sweden) and registered in the NOPHO database. A
subset of the 128 patients (43 cases) was included in a
recently reported retrospective, international study on
DS-ALL [28]. Prior to 1992, some patients may have es-
caped registration due to a less developed database, but
since 1992 data on clinical, immunophenotypic, and
genetic features of all Nordic pediatric ALL cases, at
least those <15 years of age, have been entered into the
NOPHO register, which hence is all-inclusive and truly
population-based for this age group since that time point.
All DS patients had BCP ALL, and for this reason their
clinical and genetic features were compared only with those
of non-DS BCP ALL cases diagnosed during the same time
period (n = 4,637). The 128 DS-ALL patients were treated
according to five different protocols: NOPHO ALL-1981
(n = 19), NOPHO ALL-1986 (n = 21), NOPHO ALL-1992
(n = 42), NOPHO ALL-2000 (n = 34), and NOPHO ALL-
2008 (n = 12). The corresponding distribution of the 4,637
non-DS-ALL patients was NOPHO ALL-1981 (n = 563),
NOPHO ALL-1986 (n = 828), NOPHO ALL-1992 (n =
1,554), NOPHO ALL-2000 (n = 1,128), and NOPHO
ALL-2008 (n = 564). Details on these protocols have
been reported previously [29,30]. The study was ap-
proved by the Regional Ethical Review Board at Lund
University and informed consent was obtained accord-
ing to the Declaration of Helsinki.
Genetic analyses
Chromosome banding analyses were performed using
standard methods in 16 cytogenetic laboratories in the
Nordic countries, and all abnormal karyotypes have been
centrally reviewed each year since 1996 (Sweden)/2000
(all five Nordic countries) by the Swedish and the
NOPHO Leukemia Cytogenetic Study Groups. Fluores-
cence in situ hybridization (FISH) or reverse-transcription
polymerase chain reaction (RT-PCR) analyses were used
to screen for the translocations/gene fusions t(1;19)
(q23;p13) [TCF3/PBX1], t(9;22)(q34;q11) [BCR/ABL1],
and t(12;21)(p13;q22) [ETV6/RUNX1], whereas FISH or
Southern blot analyses were used to identify 11q23/
MLL rearrangements. These targeted analyses have been
performed prospectively from 1996 in Sweden and from
2000 in the other Nordic countries, with several add-
itional cases prior to this time having been analyzed
retrospectively. During recent years, various array ana-
lyses have also been increasingly used to establish and
confirm the registered karyotypes. In the NOPHO ALL-
2008 protocol, FISH-based screening for intrachromo-
somal amplification of chromosome 21 (iAMP21) was
01
2
3
4
5
6
7
8
9
Year (1981-2010)
N
um
be
r o
f p
at
ie
nt
s
Figure 1 Number of DS patients diagnosed with ALL in the Nordic countries between 1981 and 2010.
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are given in Additional file 1: Table S1.
Statistical analysis
The PASW Statistics software for Windows (SPSS Inc.,
Chicago, IL) was used for all statistical analyses. The sig-
nificance limit for two-sided P values was set to <0.05.
Age, gender, WBC and platelet counts, types of event,
and cytogenetic subgroups were compared within the
DS-ALL group as well as between the 128 DS-ALL and0
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Figure 2 Age distribution of the DS-ALL and non-DS-ALL patients.the 4,637 non-DS-ALL cases using the chi square or the
Mann–Whitney U tests with exact calculations of P values.
Survival analyses were performed only on cases treated ac-
cording to the NOPHO ALL-1992 and ALL-2000 proto-
cols, partly because they were almost identical in risk
stratification and treatment and partly because they
comprised the majority of patients. The probabilities of
event-free survival (EFS) and overall survival (OS) were
calculated using the Kaplan-Meier method and sub-
groups were compared using the Log rank test. In the11 12 13 14 15 16 17
DS-ALL
non-DS-ALL
s
Table 1 Clinical features of the 128 DS-ALL and the 4,637
non-DS-ALL patients
Features DS-ALL (%) non-DS-ALL (%) P valuea
Gender
Female 63 (49) 2195 (47) 0.67b
Male 65 (51) 2442 (53)
Age (years)
<1 0 (0) 154 (3.3) 0.029c
1-9 95 (74) 3703 (80)
10-17 33 (26) 780 (17)
WBC count (×109/l)
0-9 61 (48) 2408 (52) 0.51c
10-49 50 (39) 1453 (31)
>50 17 (13) 776 (17)
Platelet count (×109/l)d
<50 76 (59) 2310 (50) 0.005c
50-149 41 (32) 1473 (32)
>150 6 (5) 755 (16)
EMDe
CNS 5f (3.9) 125 (2.7) NA
Mediastinal 4f (3.1) 72 (1.6)
Testis 0 (0) 15 (0.6)
CNS, central nervous system; DS-ALL, Down syndrome-related acute
lymphoblastic leukemia; EMD, extramedullary disease; NA, not analyzed due to
lack of EMD data in several instances; WBC, white blood cell.
aSignificant P values in bold type.
bChi square test.
cMann-Whitney U test.
dData on platelet counts missing in 5 DS-ALL and in 99 non-DS-ALL patients.
eData on CNS involvement missing in 16 non-DS-ALL patients, on mediastinal
mass in one DS-ALL and in 51 non-DS-ALL patients, and on testicular
involvement in 27 DS-ALL and in 990 non-DS-ALL patients.
fOne patient had CNS involvement as well as a mediastinal mass.
Lundin et al. Journal of Hematology & Oncology 2014, 7:32 Page 4 of 11
http://www.jhoonline.org/content/7/1/32analysis of EFS, events comprised induction failure, relapse,
second malignant neoplasm (SMN), and death in complete
remission 1 (DCR1). In the OS analyses, death of any cause
was the end point. Patients in continuous complete remis-
sion 1 were followed between 0 and 355 months (median
134 months).
Results
Patients
The 128 DS-ALL patients comprised 2.7% of all 4,765
BCP ALL cases diagnosed and treated in the Nordic
countries between 1981 and 2010, with the number of
DS-ALL cases per year varying between 1 and 8 (median
5; P = 0.49) during this time period (Figure 1).
Within the DS-ALL cohort, there were no significant
gender differences in age or WBC count distributions,
whereas the platelet counts were higher in girls than in
boys (median 47.0 × 109/l, range 5–359, and 26.5 × 109/l,
range 4–493, respectively; P = 0.042). Age had no impact
on the WBC and platelet counts.
The DS-ALL and non-DS-ALL patients did not differ as
regards sex ratio (male/female: 1.03 and 1.11, respectively)
and WBC counts (median 10 × 109/l, range 0.5-540, and
9 × 109/l, range 0.3-1670, respectively). The median age
was 4 years in both groups; however, the age distributions
varied significantly (Figure 2) – the age peaks were at
2 years in DS-ALL and 3 years in non-DS-ALL, and none
of the DS patients had infant ALL (P = 0.029). The platelet
counts were lower in DS-ALL than in non-DS-ALL (me-
dian 35 × 109/l; range 4–493, and 48 × 109/l; range 1–878;
P = 0.005) (Table 1).
Genetic features
Informative karyotypes (normal or abnormal) at the time
of diagnosis were available in 95 (74%) DS-ALL and in
3,283 (71%) non-DS-ALL cases (P = 0.43), with abnormal
karyotypes being more common in non-DS-ALL (79%)
than in DS-ALL (60%) (Table 2; P < 0.0001). The fre-
quencies of normal and abnormal karyotypes in DS-ALL
did not differ significantly between 1981–1995 (48% nor-
mal, 52% abnormal) and 1996–2010 (36% normal, 64%
abnormal) (P = 0.36), whereas the proportions of karyo-
typic failures/missing data (1981–1995: 21% and 1996–
2010: 4.7%) decreased significantly during the latter time
period (P < 0.001). The corresponding frequencies in
non-DS-ALL were 41% normal and 59% abnormal cases
1981–1995 and 14% normal and 86% abnormal cases
1996–2010 (P < 0.001), with the proportions of karyo-
typic failures/missing data being 53% for 1981–1995 and
10% for 1996–2010 (P < 0.001).
Among the DS-ALL patients, two (1.6%) had trisomy
21 mosaicism (the trisomic cells were involved in the
leukemic clone), one (0.8%) had a Robertsonian trans-
location [der(14;21)(q10;q10)], and one (0.8%) had acomplex constitutional unbalanced t(15;21;16) leading to
gain of 21q; the remaining 124 (97%) patients had a clas-
sical non-mosaic trisomy 21. One patient had both DS
and Klinefelter syndrome, i.e., a sex chromosome com-
plement of XXY (Additional file 1: Table S1).
The most common acquired changes in DS-ALL
were + X (14% of the 95 informative cases), deletions of
9p (13%; including some cases with microdeletions iden-
tified by array analyses), 12p (7%; including some cases
with microdeletions identified by FISH and/or array ana-
lyses), 13q (6%; the majority identified by array analyses),
and 1p (5%), +14/i(14)(q10) (5%), +17/i(17)(q10) (4%), and
gain of an extra chromosome 21 (4%). The only recurrent
translocations were t(12;21)(p13;q22), detected in 8 (15%)
of the 54 cases analyzed by FISH and/or RT-PCR, and
t(8;14)(q11;q32), found in two (2%) cases. The ALL-
associated translocations t(1;19)(q23;p13) and t(9;22)(q34;
q11) [with the P190 BCR/ABL1 transcript] were found
in single cases; no DS-ALL harbored an 11q23/MLL re-
arrangement or an iAMP21. The distributions of modal
Table 3 Survival of the DS-ALL patients treated according
to the ALL-1992/2000 protocols in relation to clinical and
genetic features
Features 5-year EFS (SE) P valuea 5-year OS (SE) P valuea
Gender
Female 0.619 (0.080) 0.46 0.693 (0.078) 0.50
Male 0.534 (0.080) 0.621 (0.081)
Age (years)
0-4 0.479 (0.106) 0.88 0.632 (0.091) 0.77
≥5 0.558 (0.076) 0.668 (0.073)
WBC count
(×109/l)
0-9 0.574 (0.086) 0.78 0.752 (0.076) 0.36
≥10 0.574 (0.077) 0.644 (0.074)
0-49 0.610 (0.061) 0.026 0.747 (0.055) 0.003
≥50 0.364 (0.145) 0.364 (0.145)
Karyotype
Abnormal 0.558 (0.076) 0.86 0.668 (0.073) 0.92
Normal 0.468 (0.116) 0.661 (0.107)
DS-ALL, Down syndrome-related acute lymphoblastic leukemia; EFS, event-free
survival; OS, overall survival; SE, standard error; WBC, white blood cell.
aSignificant P values in bold type.
Table 2 Genetic features of the DS-ALL and the
non-DS-ALL patients
Features DS-ALL (%) non-DS-ALL (%) P valuea
Karyotype
Abnormal 57 (60) 2581 (79) <0.0001
Normal 38 (40) 702 (21)
Modal numberb
Hypodiploidy 1 (1) 211 (6) <0.0001
Pseudodiploidy 37 (39) 940 (29)
Hyperdiploidy 17 (18) 329 (10)
High hyperdiploidy 2 (2) 1075 (33)
>67 chromosomes 0 (0) 26 (1)
Normal karyotype 38 (40) 702 (21)
TCF3-PBX1c
Yes 1 (2.6) 70 (4.2) 1.00
No 37 (97) 1592 (96)
BCR-ABL1c
Yes 1 (2.1) 73 (3.7) 1.00
No 46 (98) 1923 (96)
MLL rearrangementc
Yes 0 (0) 122 (7.6) 0.07
No 41 (100) 1487 (92)
ETV6-RUNX1c
Yes 8 (15) 568 (25) 0.11
No 46 (85) 1719 (75)
t(8;14)(q11;q32)
Yes 2 (2.1) 3 (0.09) NA
No 93 (98) 3280 (99.9)
iAMP21d
Yes 0 (0) 6 (1.1) NA
No 12 (100) 558 (98.9)
DS-ALL, Down syndrome-related acute lymphoblastic leukemia; iAMP21,
intrachromosomal amplification of chromosome 21; NA, not analyzed due to
too few cases.
aChi square test. Significant P values in bold type.
bHypodiploidy was defined as <47 in DS and <46 in non-DS; pseudodiploidy
as 47 in DS and 46 in non-DS; hyperdiploidy as 48–50 in DS and 47–50 in
non-DS; and high hyperdiploidy as 51–67 chromosomes in both groups.
cBased only on informative cases, i.e., on which targeted molecular genetic or
FISH analyses of these rearrangements had been performed.
dBased only on informative cases, i.e., on cases treated according to the
ALL-2008 protocol and hence screened for iAMP21.
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ALL cases (P < 0.0001), with high hyperdiploidy (51–67
chromosomes) being found in two cases only (Table 2 and
Additional file 1: Table S1). Although the frequencies of t
(1;19), t(9;22), and t(12;21) were lower in the DS-ALL
group, they did not differ significantly from the ones
observed in non-DS-ALL. Cases with t(8;14) or iAMP21
were too few to allow meaningful statistical analyses
(Table 2).Survival of the DS-ALL patients in the NOPHO
ALL-1992/2000 protocols
Of the 128 DS patients, 42 and 34 were treated according
to the ALL-1992 and ALL-2000 protocols, respectively.
There were no significant differences (P = 0.10) in 5-year
EFS of the DS-ALL patients between these treatment
regimens [pEFS 0.50 (standard error 0.077) vs. pEFS 0.67
(0.082)] or as regards 5-year OS (P = 0.31) [pOS 0.595
(0.076) vs. pOS 0.735 (0.085)]. Thus, these two protocols
were combined in the subsequent survival analyses
(Table 3). Within the DS-ALL cohort, gender, age and
karyotype (abnormal vs. normal) had no impact on EFS or
OS. The low number of ALL-associated translocations in
DS-ALL precluded detailed analyses of their prognostic
impact. However, it may be noteworthy that seven of
the eight t(12;21)-positive DS-ALL patients remain in
complete remission (Additional file 1: Table S1). There
was a significant difference in 5-year EFS (P = 0.026)
and in 5-year OS (P = 0.003) between DS-ALL patients
with WBC counts below and above 50 × 109/l (Figure 3;
Table 3).
Survival differences between the DS-ALL and non-DS-ALL
patients in the NOPHO ALL-1992/2000 protocols
Among the 4,637 non-DS-ALL patients, 1,554 and 1,128
were treated according to ALL-1992 and ALL-2000, re-
spectively. There were no significant differences (P = 0.76)
in 5-year EFS of the non-DS-ALL patients between these
two protocols [pEFS 0.782 (0.010) vs. pEFS 0.785 (0.013)]
WBC 50 x 109
WBC 0-49 x 109
4 8 12 16 20
(years)
P=0.026
WBC 0-49 x 109
WBC 50 x 109
P=0.003
4 8 12 16 20
b
Figure 3 Survival of DS-ALL patients treated according to the NOPHO ALL-1992 and ALL-2000 protocols in relation to WBC
counts <50 × 109/l vs. ≥50 × 109/l. (a) Event-free survival. (b) Overall survival.
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0.902 (0.009)]. These two protocols could hence be com-
bined when comparing DS-ALL and non-DS-ALL.
The types of event varied significantly (P = 0.005) be-
tween the DS-ALL and non-DS-ALL cases, with induction
failure being more common in DS-ALL and SMN being
observed only among non-DS-ALL patients (Table 4). NineDS-ALL patients had induction failure, of which 6 died
due to toxicity (Table 4). The frequencies of induction fail-
ure did not differ between cases with WBC counts below
or above 50 × 109/l (data not shown).
When analysing the two treatment protocols together,
both 5-year EFS and 5-year OS were significantly infer-
ior in the DS-ALL cohort (Figure 4; Table 5).
Table 4 Significant difference (P = 0.005)a in types of
event in DS-ALL and non-DS-ALL patients treated
according to the ALL-1992/2000 protocols
Events DS-ALL (% of events) non-DS-ALL (% of events)
Relapse 23 (66) 507 (80)
Induction failure 9b (26) 47 (7.4)
DCR1 3 (8.6) 48 (7.6)
SMN 0 (0) 32 (5.0)
DS-ALL, Down syndrome-related acute lymphoblastic leukemia; DCR1, death in
complete remission 1; SMN, second malignant neoplasm.
aMann-Whitney U test.
bSix of the 9 patients with induction failure died due to toxicity.
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The basic clinical features of this population-based DS-
ALL patient cohort from the Nordic countries (Table 1)
agree very well with previous studies on DS-ALL. For
example, there were no infants, no case had mature B-
cell leukemia or T-cell ALL, there were no differences
between the DS-ALL and the non-DS-ALL patients in
sex ratio, WBC counts, and median age at diagnosis, and
the platelet counts were lower in DS-ALL [4,8,11,13,
20,26]. Thus, the present series is clearly representative of
DS-ALL.
Since our study includes ALL cases diagnosed during
the last three decades, it provides data pertinent to pos-
sible time-related aspects of diagnostic routines. We had
anticipated that there could have been a bias as regards
reporting DS-ALL cases to the registry during its early
years, perhaps because some centres may have been less
inclined to give intensive treatment to children with DS
and/or to include them in the database. However, this
was clearly not the case. The incidence of DS-ALL has
been quite constant throughout the years, with no sig-
nificant variation (Figure 1). Furthermore, we have no
evidence that DS-ALL cases have been less well cytoge-
netically characterized through the years. In contrast,
although karyotypic failures/missing data for DS-ALL
were much more common 1981–1995 (21%) than be-
tween 1996 and 2010 (4.7%), the corresponding frequen-
cies in non-DS-ALL were even higher (53% and 10%,
respectively). This notwithstanding, whereas the propor-
tion of abnormal karyotypes in DS-ALL has not increased
greatly during the last few years, there has been a signifi-
cant increase in the frequency of abnormal karyotypes in
non-DS-ALL. We do not believe that this is due to tech-
nical advances in cytogenetic analyses only, which seem to
have benefited non-DS-ALL more than DS-ALL, but ra-
ther to true biological differences.
As alluded to above, DS-ALL significantly less often
displayed an abnormal karyotype (60%) compared with
non-DS-ALL (79%) (Table 2). A similarly low frequency
of clonal abnormalities (54%) was also noted in a previous
collaborative, international cytogenetic study on acuteleukemia in DS patients [26]. One reason for the higher
proportion of normal karyotypes in DS-ALL could be that
they more often harbor cytogenetically cryptic changes. In
fact, deregulation of the CRLF2 gene, either through dele-
tions of Xp22.33/Yp11.32 or by translocations between
these regions and the immunoglobulin heavy chain locus
(IGH@) at 14q32.33, both undetectable by conventional
chromosome banding analysis, is substantially more com-
mon in DS-ALL than in non-DS-ALL [17,18]. Further-
more, a “normal” karyotype in DS-ALL has an additional
chromosome 21. Perhaps fewer additional, acquired aber-
rations are needed to establish the leukemia because of
the presence of the “preleukaemic” trisomy 21, akin to
what has been suggested for ML-DS, in which GATA1
mutations are only efficient in the context of +21c [31]. In
fact, it has been demonstrated that trisomy 21 as such per-
turbs fetal lymphopoiesis [32].
In contrast to the study by Forestier et al. [26], in which
it was reported that 11% of DS-ALL cases are high hyper-
diploid, only 2% of the Nordic cases had a modal number
between 51 and 67 chromosomes [27] (Table 2). The rea-
son(s) for this pronounced difference is unclear. Although
high hyperdiploid cells are notoriously difficult to culture
in vitro and many cases may escape detection, masquerad-
ing as karyotypically normal or cytogenetic failures [33,34],
we deem it unlikely that the low frequency of such cases in
our cohort is due to technical issues. First, the proportion
of high hyperdiploid cases among the non-DS-ALL pa-
tients (33%) is on a par with other study groups [34].
Second, DNA index analyses of pediatric leukemias are
performed in clinical routine, according to the NOPHO
protocols, and they should have identified high hyperdi-
ploid cases that were cytogenetically missed. Third, most
laboratories in the Nordic countries use interphase FISH
analyses to identify t(12;21) and all use FISH to screen for
iAMP21. Since the vast majority of high hyperdiploid ALL
have tetrasomy 21 [35], such analyses would also identify
extra copies of chromosome 21 and hence suggest the
presence of high hyperdiploidy. Furthermore, Heerema
et al. [36] reported only four DS patients (0.8%) among
480 high hyperdiploid ALL cases. Thus, we believe that
there may have been a bias in reporting high hyperdi-
ploid DS-ALL cases in Forestier et al. [26].
Other ALL-associated abnormalities that were less com-
mon, but not significantly so, in DS-ALL were t(1;19),
t(9;22), 11q23/MLL rearrangements, and t(12;21) (Table 2).
However, the frequencies of t(1;19), t(9;22), and t(12;21)
were slightly higher in this study compared with those re-
ported in Forestier et al. [26]. This most likely reflects that
targeted analyses for these abnormalities were performed
in a larger proportion of Nordic DS-ALL cases. As regards
iAMP21, this aberration has been actively screened for
only in the ongoing NOPHO ALL-2008 protocol. So
far, none of 12 DS-ALL cases treated according to this
P<0.001
161284 20 24
4 8 12 16 20 24
P<0.001
b
Figure 4 Event-free survival (EFS) and overall survival (OS) of DS-ALL and non-DS-ALL patients in the NOPHO ALL-1992 and ALL-2000
combined. (a) EFS in ALL-1992/2000 (b) OS in ALL-1992/2000.
Table 5 Comparison of survival data between the DS-ALL
and non-DS-ALL patients treated according to the
ALL-1992/2000 protocols
Protocol 5-year EFS (SE) P valuea 5-year OS (SE) P valuea
DS-ALL 0.574 (0.057) <0.001 0.691 (0.054) <0.001
non-DS-ALL 0.783 (0.008) 0.894 (0.006)
DS-ALL, Down syndrome-related acute lymphoblastic leukemia; EFS, event-free
survival; OS, overall survival; SE, standard error.
aSignificant P values in bold type.
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http://www.jhoonline.org/content/7/1/32protocol has harbored an iAMP21 whereas it has been
detected in 1% of non-DS-ALL cases (Table 2). The low
frequency of iAMP21 in DS-ALL agrees well with data
from UK MRC ALL97 [37]. The only structural abnormal-
ity that seems to be more common in DS-ALL is t(8;14)
(q11;q32) (Table 2), something that has been noted also in
several previous studies [38-40]. Why most ALL-associated
abnormalities are less frequent or, as regards t(8;14), more
common in DS-ALL remain enigmatic.
The distribution of types of event differed significantly
between the DS-ALL and non-DS-ALL patients (Table 4).
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http://www.jhoonline.org/content/7/1/32The fact that induction failure was more common in the
former group was not surprising; this has been repeatedly
observed [4,11,41]. However, the lack of secondary ma-
lignant neoplasms (SMN) after treatment for DS-ALL
is noteworthy – none of the 128 DS-ALL patients in
the Nordic countries has developed SMN. Although not
stressed in previous studies, this seems to be the case also
in several other treatment trials, such as those from the
Berlin-Frankfurt-Münster (BFM), Children's Cancer Group
(CCG), and Italian Association of Pediatric Hematology
and Oncology (AIEOP) groups [10,11,41,42]. It is well
known that individuals with DS in general have a lower in-
cidence of solid tumors than non-DS-individuals [2], with
possible explanations including gains of tumor suppressor
genes on chromosome 21, impaired angiogenesis, and ac-
celerated cell ageing [43]. Whether such mechanisms could
be involved in preventing SMN in DS patients is unclear,
not least considering that most SMN are not solid tumors
but rather myelodysplastic syndromes and acute myeloid
leukemia, with the latter being clearly overrepresented in
DS as a de novo disease [2].
The only factor associated with survival in DS-ALL was
the WBC count. Patients with a WBC count ≥50 × 109/l
had significantly inferior 5-year EFS and 5-year OS com-
pared with those with lower counts (Table 3; Figure 3).
Although not surprising – a high WBC count is a well-
established risk factor in pediatric non-DS-ALL [30] – this
has not been clearly demonstrated in DS-ALL previously.
Data on improved outcome for DS-ALL have emerged
during the last few years from some treatment trials
[41,42,44], suggesting that induction and/or maintenance
therapy has improved for this patient cohort. However,
in the present study, both EFS and OS were still inferior
for the DS-ALL cohort in the combined ALL-1992/2000
protocols (Figure 4; Table 5). Whether this depends on in-
sufficient treatment intensity [45], clinical decision making
for relapsed DS-ALL, or on treatment- and/or syndrome-
related comorbidity [46] remains to be evaluated in detail.
Additional file
Additional file 1: Clinical and karyotypic data on the 128 DS-ALL
patients.
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